Valeant CEO Deposed for at Least Nine Hours by Senate Committee
- Outgoing executive appeared in D.C. ahead of April 27 hearing
- Senate, House have been investigating drug pricing practices
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. outgoing Chief Executive Officer Mike Pearson was deposed for at least nine hours on Monday by a Senate committee that’s investigating his company’s drug pricing practices, ahead of a public hearing later this month.
Pearson was led into a meeting room in the Dirksen Senate office building at about 10 a.m. Monday in Washington, complying with a congressional subpoena. During breaks and after the session ended at around 7 p.m. that evening, he declined to comment. Valeant has said it’s cooperating with the inquiry.